AspireRx Launch Opportunity to expand AspyreRx adoption across additional healthcare networks by leveraging partnerships with federally qualified health centers and payers, building on the 2024 collaboration with the American College of Lifestyle Medicine to scale access.

Strategic Partnerships Significant sales potential from integrating with existing health IT platforms (Glooko, Salesforce ecosystem) and aligning with ASCs and large health systems to streamline prescription, patient onboarding, and outcome tracking for cognitive behavioral digital therapeutics.

Breakthrough Momentum FDA Breakthrough Device Designation for MASH creates a compelling credibility signal for broader payer coverage and reimbursement discussions, enabling faster adoption in metabolic disease management portfolios.

Market Positioning Position Better as a modular digital therapeutic platform addressing root behavioral factors in cardiometabolic diseases, presenting upsell opportunities into related conditions beyond Type 2 diabetes as clinical data matures.

Scale Through SDH Leverage a distributed workforce and cross-state presence to target regional health plans and employer groups seeking cost-effective digital behavior therapies, with a focus on cost savings and improved patient outcomes.